D
Agile Therapeutics, Inc. AGRX
NASDAQ
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)
D
Sell 11/17/2023Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 11/17/2023 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 104.28% from -$8.52M to $365, earnings per share increased from -$2.1522 to -$0.2708, and net income increased 79.02% from -$3.81M to -$799.
E
Sell 3/14/2023Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 03/14/2023.
D
Sell 2/9/2023Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell 2/8/2023Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index.
D
Sell 8/15/2022Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 8/15/2022 due to a noticeable increase in the growth index, solvency index and total return index. Operating cash flow increased 80.11% from -$14.75M to -$2.93M, debt to equity declined from 6.73 to 3.76, and the quick ratio increased from 0.39 to 0.53.
D
Sell 6/6/2022Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 6/6/2022 due to a decline in the volatility index.
D
Sell 5/16/2022Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/16/2022 due to a large increase in the growth index. Earnings per share increased from -$7.9942 to -$3.78, EBIT increased 30.35% from -$22.36M to -$15.57M, and total revenue increased 16.31% from $1.51M to $1.76M.
D
Sell 5/5/2022Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D- from E+ on 05/05/2022.
E
Sell 4/20/2022Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D- on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. EBIT declined 41.74% from -$15.77M to -$22.36M, and earnings per share declined from -$0.18 to -$0.1999.
D
Sell 12/1/2021Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 12/1/2021 due to a decline in the total return index and volatility index.
D
Sell 11/9/2021Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 11/09/2021.
E
Sell 11/8/2021Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.65 to 1.54, and the quick ratio declined from 2.77 to 1.68.
D
Sell 10/19/2020Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D from D+ on 10/19/2020 due to a decline in the valuation index and volatility index.
D
Sell 10/2/2020Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D+ from D on 10/2/2020 due to an increase in the total return index, volatility index and valuation index.
D
Sell 9/8/2020Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D from D+ on 9/8/2020 due to a decline in the valuation index.
D
Sell 8/24/2020Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D+ from D on 8/24/2020 due to a major increase in the total return index, valuation index and volatility index.
D
Sell 5/1/2020Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/1/2020 due to a large increase in the total return index, solvency index and growth index. Debt to equity declined from 0.01 to 0, and operating cash flow increased 35.63% from -$5.08M to -$3.27M.
D
Sell 7/28/2017Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 7/28/2017 due to a decline in the valuation index, solvency index and efficiency index. Total capital declined 15.35% from $50.81M to $43.01M, debt to equity increased from 0.43 to 0.48, and the quick ratio declined from 3.6 to 3.32.
D
Sell 7/20/2017Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 7/20/2017 due to an increase in the valuation index and volatility index.
D
Sell 12/12/2016Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 12/12/2016 due to a decline in the valuation index, efficiency index and solvency index. Debt to equity increased from 0.29 to 0.33, and total capital declined 9.94% from $69.1M to $62.23M.
D
Sell 5/10/2016Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/10/2016 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 4.34 to 7.79, total capital increased 68.74% from $45.27M to $76.38M, and debt to equity declined from 0.52 to 0.25.
D
Sell 3/11/2016Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.96% from $48.14M to $45.27M.
D
Sell 6/1/2015Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 6/1/2015 due to a major increase in the volatility index, total return index and solvency index. The quick ratio increased from 4.47 to 11.19, and debt to equity declined from 0.41 to 0.31.
D
Sell 2/2/2015Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D- from E+ on 2/2/2015 due to an increase in the growth index and volatility index. Operating cash flow increased 262.79% from -$2.14M to -$7.78M, and EBIT increased 73.09% from -$3.49M to -$6.05M.
E
Sell 11/3/2014Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 11/3/2014 due to a substantial increase in the total return index and valuation index.
E
Sell 8/22/2014None
Agile Therapeutics, Inc. (AGRX) was downgraded to E from U on 08/22/2014.
Weiss Ratings